MannKind | MNKD - Betriebsaufwand





Betriebsaufwand Veränderung Datum
Adma Biologics USD 76.41M 6.8M 2025-12
BioCryst Pharmaceuticals USD 146.17M 534.06M 2025-12
Eli Lilly USD 10.31B 1.09B 2025-12
Halozyme Therapeutics USD 211.07M 74.73M 2025-12
Insmed USD 513.55M 109.86M 2025-12
Karyopharm Therapeutics USD 61.82M 3.24M 2024-12
MacroGenics USD 53.32M 13.68M 2025-12
MannKind USD 119.64M 56.29M 2025-12
Merck USD 10.16B 558M 2025-12
Minerva Neurosciences USD 4.52M 155.46K 2024-12
Novavax USD 126.2M 23.62M 2025-12
Novo Nordisk DKK 6.5B 32.8B 2025-06
Pfizer USD 12.91B 79.89B 2025-12
Sanofi EUR 10.51B 1.21B 2025-12
Xencor USD 81.86M 13.35M 2025-12